ProShare Advisors
KYNB

ProShare Advisors’s Kyntra Bio KYNB Stock Holding History

ProShare Advisors’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-495
Closed -$11K – 2090
2024
Q2 		$11K Sell
495
-169
-25% -$5.22K ﹤0.01% 1831
2024
Q1 		$39K Buy
664
+53
+9% +$2.28K ﹤0.01% 1934
2023
Q4 		$13.5K Sell
611
-118
-16% -$1.78K ﹤0.01% 1936
2023
Q3 		$15.7K Buy
729
+3
+0.4% +$118 ﹤0.01% 1797
2023
Q2 		$49K Buy
726
+53
+8% +$21.9K ﹤0.01% 1774
2023
Q1 		$314K Sell
673
-88
-12% -$46.6K ﹤0.01% 1188
2022
Q4 		$305K Buy
761
+60
+9% +$23K ﹤0.01% 1228
2022
Q3 		$229K Buy
701
+17
+2% +$5.47K ﹤0.01% 1315
2022
Q2 		$180K Sell
684
-347
-34% -$88.7K ﹤0.01% 1502
2022
Q1 		$310K Sell
1,031
-244
-19% -$85.1K ﹤0.01% 1609
2021
Q4 		$449K Buy
1,275
+42
+3% +$13.1K ﹤0.01% 1534
2021
Q3 		$315K Sell
1,233
-445
-27% -$158K ﹤0.01% 1514
2021
Q2 		$1.12M Buy
1,678
+211
+14% +$122K ﹤0.01% 976
2021
Q1 		$1.27M Buy
1,467
+99
+7% +$105K ﹤0.01% 863
2020
Q4 		$1.27M Buy
1,368
+315
+30% +$331K ﹤0.01% 787
2020
Q3 		$1.08M Sell
1,053
-20
-2% -$21.5K 0.01% 702
2020
Q2 		$1.09M Buy
1,073
+352
+49% +$327K 0.01% 681
2020
Q1 		$627K Sell
721
-535
-43% -$532K ﹤0.01% 690
2019
Q4 		$1.35M Sell
1,256
-112
-8% -$114K 0.01% 715
2019
Q3 		$1.26M Sell
1,368
-35
-2% -$38.4K 0.01% 691
2019
Q2 		$1.58M Sell
1,403
-213
-13% -$233K 0.01% 640
2019
Q1 		$2.2M Buy
1,616
+55
+4% +$74.6K 0.01% 580
2018
Q4 		$1.81M Sell
1,561
-286
-15% -$321K 0.01% 590
2018
Q3 		$2.81M Buy
1,847
+49
+3% +$75.5K 0.02% 539
2018
Q2 		$2.81M Sell
1,798
-87
-5% -$113K 0.02% 558
2018
Q1 		$2.18M Sell
1,885
-296
-14% -$390K 0.01% 602
2017
Q4 		$2.58M Buy
2,181
+167
+8% +$209K 0.02% 552
2017
Q3 		$2.71M Buy
2,014
+368
+22% +$388K 0.02% 499
2017
Q2 		$1.33M Buy
1,646
+56
+4% +$39K 0.01% 653
2017
Q1 		$980K Sell
1,590
-416
-21% -$253K 0.01% 752
2016
Q4 		$1.07M Buy
2,006
+182
+10% +$90.9K 0.01% 743
2016
Q3 		$944K Sell
1,824
-292
-14% -$138K 0.01% 698
2016
Q2 		$868K Buy
2,116
+44
+2% +$20.1K 0.01% 765
2016
Q1 		$1.1M Sell
2,072
-180
-8% -$89.7K 0.02% 673
2015
Q4 		$1.72M Buy
+2,252
New +$1.49M 0.02% 556

Other funds holding KYNB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
GC
GFG Capital Miami, Florida $363M AUM 45.53% 1-Year Est. Return

ProShare Advisors's KYNB Position: Q3 2024 in Review

ProShare Advisors sold out of Kyntra Bio (KYNB) in Q3 2024, closing a stake of 495 shares — an estimated $11K sold.

ProShare Advisors first reported a position in KYNB in Q4 2015 and held it in 35 quarters. The position peaked at $2.81M in Q2 2018. 70 funds tracked by Wall St. Rank hold KYNB as of Q3 2024.

  • ProShare Advisors reported no remaining Kyntra Bio position as of Q3 2024 after selling out during the quarter.
  • ProShare Advisors sold 495 Kyntra Bio shares in Q3 2024, an estimated $11K.
  • ProShare Advisors first reported a position in Kyntra Bio in Q4 2015 and held it in 35 quarters.
  • ProShare Advisors's Kyntra Bio position peaked at $2.81M in Q2 2018.
  • 70 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2024.

Based on ProShare Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.